CD2.AX down 42% to A$0.49 on ASX 30 Jan 2026: what investors should watch
CD2.AX stock plunged 42.01% to A$0.49 at market close on the ASX on 30 Jan 2026, making it one of the day’s top losers. The fall follows heavy intraday selling after the stock opened at A$0.50 and printed a day high of A$0.50 and day low of A$0.49. Volume rose to 67,104 shares versus an average of 64,571, signalling outsized trading interest. This note unpacks price drivers, fundamentals, technicals and short-term forecasts for CD Private Equity Fund II (CD2.AX) on the Australian market.
Price action and immediate drivers for CD2.AX stock
CD2.AX stock closed at A$0.49, down A$0.36 or 42.01% from the previous close of A$0.85. One-day change far outpaced 5-day (-33.99%) and 1-month (-24.63%) moves, showing concentrated selling today. Higher-than-normal volume of 67,104 shares (relVolume 21.10) suggests forced selling or a clustered exit rather than normal profit-taking.
Fundamentals and valuation snapshot
CD Private Equity Fund II (CD2.AX) reports an EPS of 0.20 and a trailing PE of 2.53, based on available data. Market capitalisation stands near A$26,501,938.00 with 52,479,086 shares outstanding. The fund-level ratios show limited public operating metrics, and book-value style ratios are not available, which raises valuation uncertainty for public investors.
Technical picture and volatility signals
Momentum indicators were stretched before the drop: RSI was 87.30 (overbought) and ADX 44.43 (strong trend). Bollinger Band width and ATR (0.02) show elevated short-term volatility. These signals align with a sharp reversal; short-term traders should watch support at A$0.49 and resistance near the 50-day average of A$0.71.
Meyka grade, model forecast and analyst context
Meyka AI rates CD2.AX with a score out of 100: 62.93 (Grade B, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a monthly price of A$0.72 (+46.94% vs current A$0.49), a quarterly target of A$0.71 (+44.90%), and a yearly projection of A$0.44 (-10.28%). These are model-based projections and not guarantees.
Sector context and risk drivers in Financial Services
CD2.AX sits in the Financial Services sector and Asset Management industry where average PE is 22.42 and average ROE is 12.30%. The fund’s concentrated exposure to small-to-mid-market US private funds amplifies liquidity and valuation risk compared with listed asset managers. Key risks include illiquid underlying holdings, FX exposure and distribution timing on unlisted assets.
Catalysts, opportunities and trading considerations
Near-term catalysts include the next earnings/announcement cycle and any update from the fund sponsor on NAV or distributions. Opportunities exist if the market overreacts to short-term news and the fund’s NAV supports higher prices. For traders, maintain strict stop levels and monitor average daily volume and dealer quotes because liquidity can evaporate quickly in single-name fund stocks.
Final Thoughts
CD2.AX stock’s 42.01% drop to A$0.49 on the ASX on 30 Jan 2026 marks a clear short-term sell-off driven by elevated volume and stretched technicals. Fundamentals show an EPS of 0.20 and a low trailing PE of 2.53, but public metrics are thin and book-value ratios are unavailable, which complicates valuation. Meyka AI’s forecast model projects a monthly price of A$0.72 (implied upside 46.94%) and a quarterly price of A$0.71 (implied upside 44.90%), while the one-year projection is A$0.44 (implied downside 10.28%) compared with today’s A$0.49. Investors should view these model outputs as scenario guides rather than guarantees. For ASX traders, the main takeaways: liquidity risk is elevated, catalysts are tied to fund-level NAV updates and distributions, and the technical picture suggests possible short-term bounce or further weakness if selling persists. We use this analysis as an AI-powered market analysis platform to surface data-driven angles; always cross-check NAV updates and sponsor announcements before acting.
FAQs
Why did CD2.AX stock fall so sharply today?
CD2.AX stock fell due to heavy intraday selling on 30 Jan 2026, elevated volume (67,104 shares) and stretched technicals (RSI 87.30). Limited public metrics and illiquid underlying assets likely amplified the move.
What is Meyka AI’s forecast for CD2.AX stock?
Meyka AI’s forecast model projects a monthly price of A$0.72 (+46.94% from A$0.49), a quarterly price of A$0.71 (+44.90%), and a yearly price of A$0.44 (-10.28%). Forecasts are model-based and not guarantees.
Is CD2.AX stock a buy after the drop?
Meyka AI currently gives CD2.AX a Grade B (score 62.93), suggestion HOLD. The fund shows attractive trailing PE but has liquidity and valuation uncertainty; investors should wait for NAV or sponsor updates.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
